Figures
Abstract
Background
The interleukin-28B (IL28B) gene polymorphism is a strong baseline predictor of sustained virological response (SVR) in hepatitis C virus (HCV) treatment. The length of thymine—adenine dinucleotide repeats, or (TA)n, in the regulatory region of IL28B can affect interferon transcription. In order to determine predictive values in HCV infection, we explored the correlation among factors including (TA)n genotypes, clinical features, interferon-λ-3 (IFNL3) and interferon-λ-4 (IFNL4) polymorphisms, and HCV treatment outcome.
Methods
Sera from 492 patients with chronic HCV infection, 101 individuals with spontaneous HCV clearance and 123 healthy blood donors (control group) were analyzed. Genotyping of the (TA)n was performed by direct sequencing. The rs12979860 (IFNL3) was identified using nested PCR and sequencing, while ss469415590 (IFNL4) was identified by real-time PCR.
Results
The distribution of (TA)n was similar between individuals with spontaneous HCV clearance and chronic HCV infection, but differed significantly from healthy controls. Individuals with both (TA)n alleles ≥12 had significantly higher SVR rate compared to individuals with at least one (TA)n <12 allele. This strong correlation was seen for patients infected with HCV-1, HCV-3, and HCV-6. The (TA)n genotypes were not associated with HCV viral load, ALT levels and liver stiffness, but were correlated with platelet counts (p<0.001). In contrast, rs12979860 (CC) and ss469415590 (TT/TT) genotypes were associated with higher SVR rated only in patients with HCV-1.
Conclusions
The (TA)n genotypes were not associated with spontaneous clearance of HCV infection but associated with treatment response in patients infected with HCV-1, HCV-3 and HCV-6. In contrast, IFNL3 and IFNL4 polymorphisms were predictive of treatment outcome only for patients infected with HCV-1.
Citation: Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y (2015) Prevalence of Thymine—Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. PLoS ONE 10(5): e0125400. https://doi.org/10.1371/journal.pone.0125400
Academic Editor: Golo Ahlenstiel, University of Sydney, AUSTRALIA
Received: February 10, 2015; Accepted: March 23, 2015; Published: May 4, 2015
Copyright: © 2015 Thong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: This work was supported by grants WCU007-HR-57 and WCU001-HR-57 from the National Research University Project, Office of Higher Education Commission, the Research Chair Grant from NSTDA, CU56-HR01 from Chulalongkorn University Centenary Academic Development Project, RES560530093 and RES560530155 from the Ratchadaphiseksomphot Endowment Fund of Chulalongkorn University, DPG5480002 from the Outstanding Professor of the Thailand Research Fund, The Graduate Scholarship for Neighboring Countries of Chulalongkorn University, SCG and MK Restaurant Company Limited. This research was also supported by Ratchadaphiseksomphot Endowment Fund for a postdoctoral fellowship, Chulalongkorn University, to Rujipat Wasitthankasem. The authors also received funding from SCG and MK Restaurant Company Limited. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors received funding from commercial sources, SCG and MK Restaurant Company Limited. However, this does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Introduction
Hepatitis C virus (HCV) infection is a significant global public health problem affecting an estimated 160 million people (~2.35% of the population) worldwide [1]. The progression to chronic HCV sometimes necessitates the need for liver transplantation and is often the leading cause of hepatocellular cancer [2]. A combination of pegylated interferon (PEG-IFN) combined with ribavirin (RBV) for the duration of 24 to 48 weeks has been the standard-of-care therapy for HCV infection for the past decade. Virus genotype and host factors such as age, sex, race, fibrosis, and steatosis can determine the treatment outcome [3–5]. In 2009, several genome-wide association studies reported that single nucleotide polymorphisms (SNPs) upstream of the interleukin-28B (IL28B) gene, which encodes interferon-λ-3 (IFNL3), were strongly associated with response to PEG-IFN/RBV therapy and spontaneous HCV clearance [6–8]. The rs12979860 of CC genotype is associated with a two-fold greater sustained virological response (SVR) rate than the TT genotype [6]. Interestingly, the gene frequency of C allele is much higher in European and Asian ancestries than in African ancestry. Recently, it was shown that the polymorphism in IFN-λ-4 (IFNL4) gene, ss469415590 of TT genotype, is more strongly associated with treatment-induced response and spontaenous HCV clearance than rs12979860 in Europeans and Asian, but especially in individuals of African ancestry [9].
Recently, an insertion/deletion polymorphism in the promoter region of IL28B consisting of thymine—adenine dinucleotide repeats (TA)n has been linked to IL28B gene expression. The length of (TA)n reportedly varies from 10 to 18 repeats with the most frequent genotype of 12/12 [10]. Luciferase assay showed that the transcriptional activity of the promoter increased gradually with increasing (TA)n length. Therefore, (TA)n could be associated with the transcriptional activity of IL-28B and could potentially be used to improve predictions of the response to interferon-based HCV treatment. In this study, we focused on the distribution of the length of (TA)n and the correlation of (TA)n genotypes with treatment outcome, clinical features, IL28B and IFNL4 polymorphisms in HCV infection.
Patients and Methods
Patients
The study followed the Helsinki Declaration on medical research. The study obtained written informed consents from patients and the protocol was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No. 517/57). A total of 593 HCV-infected Thai individuals comprising of 101 patients with spontaneous HCV clearance (defined as anti-HCV sero-positive and undetectable HCV RNA in patients without previous antiviral treatment) and 492 patients with chronic HCV (defined as anti-HCV sero-positive and detectable HCV RNA for more than 6 months) were followed-up at King Chulalongkorn Memorial Hospital in Bangkok, Thailand. Among the 492 patients chronically infected with HCV, 264 underwent treatment and 228 did not. Patients who received ≥ 80% of the recommended dose of PEG-IFN/RBV were considered assessable for response to treatment. SVR was defined as an absence in detectable HCV RNA in serum at 24 weeks after treatment termination. All other patients were considered non-responders. For comparison, 123 healthy Thai blood donors who tested negative for HBsAg and anti-HCV comprised the control group (Fig 1). Among these, 225 individuals from a previous study to investigate the association of rs12979860 and ss469415590 with HCV treatment response [11] were included in this study for better data analysis.
Methods
Clinical, biochemical, liver assessment evaluation and SNP genotyping.
During screening, we obtained patient information including demographical data (age, sex, height, weight, and body mass index) and laboratory tests at baseline including blood cell counts, aspartate transaminase (AST) and alanine transaminase (ALT). Liver fibrosis was evaluated through fibroscan stiffness. HCV treatment was also extracted from clinical database.
Two SNPs, rs12979860 (IL28B) and ss469415590 (IFNL4), were genotyped using nested PCR [11] and real-time PCR [9], respectively. For rs12979860, PCR products were sequenced and the major (CC) and minor (TT) alleles were determined. In order to investigate an upstream variation of IL28B, ss469415590, real-time PCR using the Taqman genotyping assay with MGB probes (Applied Biosystems, Carlsbad, CA) was performed as previously described [9, 12]. TT and ΔG were major and minor alleles, respectively.
HCV RNA quantification and genotypes.
HCV RNA quantification was performed using the real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (COBAS TaqMan HCV assay, Roche Diagnostics, Basel, Switzerland) according to the manufacturer’s instructions.
HCV genotypes were determined by nucleotide sequencing of the core and NS5B regions followed by phylogenetic analysis as previously described [13].
TA repeat genotyping.
Genomic DNA of patients was extracted from peripheral blood mononuclear cells (PBMC) or plasma using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). PCR was performed using primers TA-CU-R (5’-CAATTCTTGAGCAGAGCCTCA-3’) and TA-CU-F (5’- GGAAGGTATGTTCCCAAGAGG-3’) and contained 5 μL DNA, 5 pmol of each primer, 10 μl of 2x Perfect Taq Plus MasterMix (5 PRIME, Gaithersburg, MD) in a total volume of 25 μl. The amplification cycles were: 94°C for 5 min, followed by 40 cycles of denaturation at 94°C for 30 sec, annealing at 54.9°C for 30 sec, extension at 72°C for 30 sec, and a final extension at 72°C for 7 min. PCR fragment was resolved by 2% agarose gel electrophoresis. PCR products were purified using GelExtract Mini Kits (5 PRIME, Gaithersburg, MD) and subjected to sequencing (First BASE Laboratories, Selangor, Malaysia) using both forward and reverse primers. The length and genotypes of TA repeat were analyzed manually based on the chromatograms (Chromas LITE, version 2.01) and compared to the reference sequence retrieved from GenBank (http://www.ncbi.nlm.nih.gov/).
Data analysis.
The Mann-Whitney U test or Student’s test was used to compare continuous variables, and the χ2 test or Fisher’s exact test was used to compare categorical variables. The Spearman rank correlation was used to evaluate the relationships among variables. All data were analyzed using SPSS Statistic Software Package for Windows version 20.0 (SPSS, Chicago, IL). Statistical significance was set at p<0.05 and all tests were two-tailed. Numerical data are presented as mean +/- standard deviation (SD) or median and interquartile range (IQR).
Results
Patients with spontaneous HCV clearance, chronic HCV, and the control group had comparable mean age, body mass index (BMI), and IL28B genotype distribution (Table 1). Chronic HCV group had slightly different IFNL4 and (TA)n genotype distribution compared to other groups, but these values were not statistically significant. However, twice as many males than females had chronic HCV (p<0.001).
Overall distribution of the allele frequencies of (TA)n in the study population
When both alleles from all 716 individuals in this study were examined (1432 alleles altogether), the observed variation of (TA)n ranged from 6 to 16 with the mode of 12 (91.7%) (Fig 2). The second and third most frequent (TA)n were 13 (4.0%) and 10 (2.1%), respectively. Other (TA)n genotypes comprised less than 1% each, and no (TA)n of 9 was observed.
Genotype (TA)n of 12 was predominant in all 3 groups (Fig 3A). Although all individuals had (TA)n of 13, individuals in the spontaneous clearance and chronic HCV groups did not have (TA)n >13. As a result, these groups had significantly fewer (TA)n >12 than the control group (p<0.001). Furthermore, (TA)n <10 was not observed in the control group. Comparison between the spontaneous clearance and chronic HCV groups showed that there was no significant difference in the frequency of allele (TA)n >12 (p = 0.217) or allele (TA)n <10 (p = 0.352) (Fig 3B).
(A) Allele frequency of (TA)n distribution in the control, spontaneous clearance, and chronic HCV groups (n = 1432). (B) The frequency distribution of (TA)n genotypes with <12, 12 and >12 alleles in control, spontaneous clearance, and chronic HCV groups (n = 1432).
Prevalence of (TA)n genotypes in spontaneous clearance, chronic HCV, and control groups
For the purpose of analysis, we defined an individual as homozygous for (TA)n genotype when that person possessed the same (TA)n for both alleles. In contrast, an individual is heterozygous for (TA)n genotype when that person possessed different (TA)n alleles. When all 3 groups were analyzed, we found that the (TA)n genotype was 94.8% homozygous (679/716) and 5.2% heterozygous (37/716). The most prevalent (TA)n homozygous genotype was 12/12, meaning that an individual possessed (TA)n of 12 for both alleles. When analyzing each group separately, there were more individuals with (TA)n of 12/12 in the spontaneous clearance group than in the control or chronic HCV groups (97.0%, 89.8%, and 91.1%, respectively).
To further simplify the analysis for individuals with heterozygous (TA)n, we defined an individual genotype "L" when both alleles were ≥ 12 and “S” when at least one allele is <12. Using this definition, the most prevalent heterozygous (TA)n genotype in all 3 groups was L (Fig 4). Genotype L was less frequent in the spontaneous clearance (94.4%) and chronic HCV (95.2%) groups than the control group (99.2%) (p<0.001). The difference in genotype L between spontaneous clearance and chronic HCV groups was not statistically significant (p = 0.487). In contrast, genotype S was more frequent in the spontaneous clearance (4.61%) and chronic HCV (3.85%) groups compared to the control group (0.81%) (p<0.001).
The (TA)n genotype is defined as “L” (when both alleles are ≥ 12) and “S” (when at least one allele is <12).
SVR rates according to (TA)n, rs12979860 and ss469415590
The 264 individuals with chronic HCV underwent PEG-IFN/RBV therapy. When the (TA)n <12, SVR and non-SVR rates were similar (1.70% versus 1.33%, p = 0.427) (Fig 5A). In contrast, individuals with (TA)n ≥12 were more likely to have SVR than non-SVR (79.36% versus 17.61%, p<0.001). Furthermore, individuals with genotype L had significantly higher SVR rate than those with genotype S (84.9% vs. 53.8%, p<0.001). Collectively, this observation shows striking concordance for all HCV genotypes (HCV-1: 87.0% vs. 20.0%, p<0.001; HCV-3: 85.3% vs. 25.0%, p<0.001; and HCV-6: 89.5% vs. 33.3%, p<0.001) (Fig 5B).
(A) Association of (TA)n with SVR to PEG-IFN/RBV therapy among individuals with chronic HCV. (B) Percentage of (TA)n genotypes L and S relative to SVR in individuals with chronic HCV who underwent PEG-IFN/RBV therapy. The (TA)n genotype is defined as “L” (when both alleles are ≥ 12) and “S” (when at least one allele is <12).
Overall, significantly higher SVR rates were observed in chronic HCV with the favorable CC genotype than non-CC genotype for rs12979860 (84.2% vs. 59.5%, p<0.001) and TT/TT genotype than non-TT/TT genotype for ss469415590 (84.9% vs. 53.8%, p<0.001) (Fig 6A and 6B). The differences in SVR between favorable and unfavorable genotypes for both rs12979860 and ss469415590 were greatest for HCV-1. For rs12979860, 88.9% of patients with CC genotype achieved SVR compared to 45.8% of patients with non-CC genotype (p<0.001). For ss469415590, 90.3% of patients with TT/TT genotype achieved SVR compared to 41.7% of patients with non-TT/TT (p<0.001). The differences in SVR for HCV-3 and HCV-6, however, were not statistically significant. Although results from our previous study suggested association between rs12979860 IL28B and ss469415590 IFNL4 (p<0.001), these polymorphisms were not associated with (TA)n (p = 0.129 with rs12979860, p = 0.108 with ss469415590 IFNL4, respectively).
Association of (TA)n genotypes with clinical parameters
Several clinical parameters were examined in patients with chronic HCV (Table 2). Individuals with (TA)n genotypes S and L did not demonstrate statistically significant differences in hemoglobin (p = 0.975) or serum ALT levels (p = 0.199). Similarly, (TA)n genotypes did not correlate with liver stiffness (p = 0.294) or HCV RNA (p = 0.305). However, (TA)n genotype S correlated with increased platelet counts (p<0.001).
Discussion
Host genetic factors can affect the outcome of HCV infection resulting in either spontaneous clearance from acute infection without treatment or persistence leading to chronic HCV and liver cirrhosis. Polymorphisms near the IL28B gene can determine the outcome of infection and the response to treatment. In the present study, we explored the overall prevalence of (TA)n genotypes among Asians of Thai descent with HCV infection resulting in natural clearance or chronic HCV. We found that the variation of (TA)n ranged from 6 to 16 and the most frequent (TA)n was 12 (91.73%) in our population. This finding was consistent with an earlier study in a Japanese cohort, which also found that 75% of individuals examined possessed (TA)n of 12 [10]. The allele <10 (TA)n was significantly more frequent in the spontaneous clearance and chronic HCV groups than in the healthy controls (p<0.001). This difference may in part be attributed to the genetic background represented by the fewer number of controls (n = 123) compared to infected individuals (n = 593). Otherwise, the allele >12 (TA)n was found in significantly higher number in healthy individuals group compared with spontaneous clearance and chronic HCV groups (p<0.001). Although the determination of the (TA)n genotypes was performed manually from chromatograms, two independent sequencing experiments were done for each sample to ensure data reproducibility.
Previous studies found that transcription of IL-28B was upregulated in the CC genotype of rs12979860, which was associated with SVR [7, 8, 14], suggesting that the expression levels of IL-28B could be one of the key factors to clear HCV under PEG-IFN/RBV therapy and could also affect spontaneous clearance of acute HCV infection [15], whereas the length of (TA)n in the regulatory region of IL-28B could affect the regulation of IL-28B transcription [10]. The most prevalent (TA)n genotype in our population was when both alleles were ≥12, with higher frequency in healthy individuals (99.2%) compared to spontaneous clearance (94.4%) and chronic HCV (95.2%) (p<0.001). The distribution of the (TA)n genotype S (when at least one allele was <12) was similar among HCV-infected individuals, but interestingly, the (TA)n genotype S was significantly more frequent in the spontaneous clearance and chronic HCV groups than in the healthy controls (p<0.001). Although we confirmed previous observations that favorable SNPs rs12979860 (CC) and ss469415590 (TT/TT) strongly correlated with improved SVR with HCV-1, but not HCV-3, and HCV-6, we found that (TA)n ≥12 correlated with increase SVR for HCV-1, -3, and -6.
A recent study from Japan demonstrated the promise of (TA)n genotype in predicting spontaneous HCV clearance [16]. The most frequent allele of (TA)n found in that Japanese cohort was also 12, which accounted for approximately 80% of individuals. In contrast, African-American cohort in that study demonstrated a gradient of (TA)n alleles ranging from 6 to 18, and although allele 12 was the most common, it only accounted for 30% of the individuals. More importantly, African-Americans with longer (TA)n were significantly associated with spontaneous HCV clearance, which attest to the promise of the predictive ability of (TA)n towards desirable clinical outcome in HCV infection.
Several SNPs in linkage disequilibrium upstream or within the IL28B gene on chromosome 19q13 are strongly associated with SVR to PEG-IFN/RBV therapy [7, 8, 14]. One such polymorphism, rs12979860 (CC) genotype, is associated with greater rate of SVR than CT or TT genotypes in European-Americans, African-Americans, and Hispanics infected with HCV-1 [6]. In particular, African-Americans with the CC genotype responded better to treatment than European-Americans with the TT genotype, suggesting that an individual’s rs12979860 genotype is a better predictor of SVR than ethnicity. Furthermore, it is a better predictor of HCV clearance, whether natural or in response to treatment, than the baseline viral load or fibrosis. This finding has been confirmed with Egyptians, Europeans, and Sub-Sahara Africans infected with HCV-4 [17, 18].
Another variant in the upstream region of IFNL3, designated as IFNL4, is also associated with treatment efficacy in HCV-infected patients [9]. This region, ss469415590, harbors a dinucleotide variant that is found in two alternative forms (ΔG or TT alleles). The ss469415590 is more strongly associated with treatment response of patients infected with HCV-1 than rs12979860 [9]. However, 20% of patients show discordance between IL28B genotype and the response, suggesting other factors including (TA)n genotypes might be involved in HCV clearance. The lack of association between rs12979860 (IL28B) and ss469415590 (IFNL4) and the (TA)n in this study may be unique to the Thai cohort as compared to other population. Another possibility may be that our study was under-powered and therefore could not identify such association.
The TA dinucleotide repeats, located precisely at the transcriptional start site of IL-28B gene, could be a biomarker for improved prediction of the response to interferon-based HCV treatment [10]. We demonstrated the correlation of (TA)n genotypes with SVR. The (TA)n ≥12 in the promoter region of IL28B was associated with HCV spontaneous clearance. It is not clear whether the variation originates from genetic or epigenetic mechanisms [19], and further studies will be needed to explore this observation in other populations. There have been several reports that implicated IL28B genotypes in inflammatory status and progression of fibrosis as measured by clinical parameters (ALT levels, alpha-fetoprotein, histological activity, levels of fibrosis and platelet-derived growth factor) [20, 21]. In our study, the baseline serum ALT level was significantly higher in patients with rs12979860 CC genotype compared to patients with non-CC genotype (p = 0.011). Similar observations were found in patients with ss469415590 TT/TT genotype compared to those with non-TT/TT genotype (p = 0.028). There were no significant differences in the baseline viral load between patients with rs12979860 CC and non-CC genotypes (p = 0.075), and patients with ss469415590 TT/TT genotype compared to those with non-TT/TT (p = 0.083). Finally, the rs12979860 and ss469415590 polymorphisms were not correlated with levels of fibrosis and platelet counts. To our knowledge, this study is the first to assess (TA)n genotypes in relation to clinical characteristics in HCV-infected patients. Although (TA)n genotypes were not associated with HCV viral load, liver inflammatory activity and liver fibrosis, they correlated with platelet counts (p<0.001). In clinical practice, genotyping HCV-infected patients to examine (TA)n may predict the effectiveness of PEG-IFN/RBV therapy even before treatment has begun. Since approximately 2.2% of the Thai population has chronic HCV and financial burden can restriction access to needed antiviral treatment, the ability to reliably predict efficacy of therapy will be useful in the overall disease management.
Since many polymorphisms are associated with IL-28B and at least (TA)n has been shown to regulate IL-28B transcription, this cytokine likely influence HCV clearance under PEG-IFN/RBV therapy and could also affect spontaneous clearance of acute HCV infection [15]. Administration of IL-28B has been shown to have antiviral effects [22–24], therefore lower expression of IL-28B as a result of unfavorable polymorphism might lead to a decrease in this effect.
Not only an individual’s genetic background plays an important role in the course of HCV infection, viral genotypes can also determine the course of infection. The observation that rs12979860 and ss469415590 polymorphisms were associated equally with the treatment outcome in response to PEG-IFN/RBV therapy in patients with HCV-1 infection, but not with HCV-3 and HCV-6, suggest that viral factors may also influence SVR in patients. Although significant differences between ethnicities in response to PEG-IFN/RBV therapy were reported [25], there were no significant associations between IL28B genotypes and response to PEG-IFN/RBV in patients infected with HCV genotype 2 or 3 [5]. In addition, some studies showed that the IL28B genotype did not predict response to treatment in HCV-5 and HCV-6 [26, 27].
In summary, our results demonstrated that (TA)n genotypes was strongly linked to treatment response to PEG-IFN/RBV therapy in HCV-infected patients of Asian descent regardless of the viral genotype and led to a higher rate of SVR. Thus, prescreening for (TA)n could assist clinical decision-making for the treatment of HCV infection and will be useful for making decisions on suitable regimens and treatment duration in patients in the forthcoming era of direct acting antiviral drugs.
Acknowledgments
We would like to express our gratitude to the entire staff of the Center of Excellence in Clinical Virology, the Gastroenterology Unit in the Department of Medicine, the Research Unit of Hepatitis and Liver Cancer, the Department of Biochemistry, the Faculty of Medicine at Chulalongkorn University and Hospital, the Thai Red Cross Society, and the Scholarship Program for Neighboring Countries, Chulalongkorn University.
Author Contributions
Conceived and designed the experiments: VDT PT YP. Performed the experiments: VDT RW. Analyzed the data: VDT SV. Contributed reagents/materials/analysis tools: VDT RW. Wrote the paper: VDT SV YP.
References
- 1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2011;17(2):107–15. pmid:21091831.
- 2. Berg CL, Steffick DE, Edwards EB, Heimbach JK, Magee JC, Washburn WK, et al. Liver and intestine transplantation in the United States 1998–2007. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009;9(4 Pt 2):907–31. pmid:19341415.
- 3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England journal of medicine. 2002;347(13):975–82. pmid:12324553.
- 4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65. pmid:11583749.
- 5. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45, 45 e1–7. pmid:20060832.
- 6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. pmid:19684573.
- 7. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature genetics. 2009;41(10):1105–9. pmid:19749757.
- 8. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature genetics. 2009;41(10):1100–4. Epub 2009/09/15. pmid:19749758.
- 9. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature genetics. 2013;45(2):164–71. pmid:23291588.
- 10. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PloS one. 2011;6(10):e26620. pmid:22046316.
- 11. Akkarathamrongsin S, Thong VD, Payungporn S, Poovorawan K, Prapunwattana P, Poovorawan Y, et al. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. Journal of medical virology. 2014;86(9):1482–90. pmid:24782280.
- 12. Akkarathamrongsin S, Sugiyama M, Matsuura K, Kurbanov F, Poovorawan Y, Tanaka Y, et al. High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatology research: the official journal of the Japan Society of Hepatology. 2010;40(10):956–62. pmid:20887330.
- 13. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, Tangkijvanich P, Tanaka Y, et al. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. Journal of medical virology. 2010;82(2):257–62. pmid:20029811.
- 14. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139(5):1577–85, 85 e1–3. pmid:20708617.
- 15. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. pmid:19759533.
- 16. Hiramine S, Sugiyama M, Furusyo N, Uto H, Ido A, Tsubouchi H, et al. A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. Journal of gastroenterology. 2015. pmid:25735432.
- 17. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England journal of medicine. 2011;364(25):2405–16. pmid:21696307.
- 18. Asselah T, De Muynck S, Broet P, Masliah-Planchon J, Blanluet M, Bieche I, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of hepatology. 2012;56(3):527–32. pmid:21951981.
- 19. Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. Journal of gastroenterology and hepatology. 2014;29(2):241–9. pmid:24325405.
- 20. Aoki Y, Sugiyama M, Murata K, Yoshio S, Kurosaki M, Hashimoto S, et al. Association of serum IFN-lambda with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. Journal of gastroenterology. 2014. pmid:25501286.
- 21. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. Journal of hepatology. 2011;54(5):859–65. pmid:21145813.
- 22. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008;180(4):2474–85. pmid:18250457.
- 23. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. Journal of virology. 2006;80(9):4501–9. pmid:16611910.
- 24. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nature medicine. 2006;12(9):1023–6. Epub 2006/08/15. pmid:16906156.
- 25. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England journal of medicine. 2009;361(6):580–93. pmid:19625712.
- 26. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut. 2012;61(11):1640–1. pmid:22345656.
- 27. Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. Journal of viral hepatitis. 2013;20(7):470–7. pmid:23730840.